MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Home・Lista de Ações・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Fechado

SetorSaúde

21.46

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

21.46

Máximo

21.47

Indicadores-chave
By Trading Economics
Rendimento	-1.6M -21M
Vendas	14M 54M
Margem de lucro	-39.611
Funcionários	178
EBITDA	-3.8M -23M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	-2.84% downside

Dividendos
By Dow Jones
Próximos Ganhos	5 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	1B 2.2B
Abertura anterior	21.46
Fecho anterior	21.46

Sentimento de Notícias

By Acuity

50%

162 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

6.26 / 7.47 Suporte e Resistência

Day One Biopharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de abr. de 2026, 23:26 UTC

Ações em Alta

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16 de abr. de 2026, 20:41 UTC

Grandes Movimentos do Mercado

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16 de abr. de 2026, 23:49 UTC

Conversa de Mercado

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16 de abr. de 2026, 23:45 UTC

Conversa de Mercado

Nikkei May Decline After Hitting Record High -- Market Talk

16 de abr. de 2026, 23:33 UTC

Conversa de Mercado

Notícias Principais

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16 de abr. de 2026, 22:51 UTC

Conversa de Mercado

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16 de abr. de 2026, 22:08 UTC

Ganhos

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Ganhos

Tech, Media & Telecom Roundup: Market Talk

16 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

16 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Notícias Principais

Basic Materials Roundup: Market Talk

16 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Ganhos

Health Care Roundup: Market Talk

16 de abr. de 2026, 20:49 UTC

Ganhos

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16 de abr. de 2026, 20:43 UTC

Ganhos

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 de abr. de 2026, 20:40 UTC

Conversa de Mercado

Ganhos

Global Equities Roundup: Market Talk

16 de abr. de 2026, 20:40 UTC

Conversa de Mercado

Ganhos

Netflix Says Engagement Quality Hits New High -- Market Talk

16 de abr. de 2026, 20:30 UTC

Ações em Alta

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16 de abr. de 2026, 20:25 UTC

Ganhos

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 de abr. de 2026, 20:23 UTC

Ganhos

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16 de abr. de 2026, 20:19 UTC

Ganhos

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16 de abr. de 2026, 20:17 UTC

Ganhos

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16 de abr. de 2026, 20:17 UTC

Ganhos

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16 de abr. de 2026, 20:16 UTC

Ganhos

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16 de abr. de 2026, 20:16 UTC

Ganhos

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16 de abr. de 2026, 20:16 UTC

Ganhos

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16 de abr. de 2026, 20:16 UTC

Ganhos

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Comparação entre Pares

Variação de preço

Day One Biopharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

-2.84% parte inferior

Previsão para 12 meses

Média 20.86 USD -2.84%

Máximo 21.5 USD

Mínimo 17 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Day One Biopharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

9 ratings

Comprar

Manter

Vender

Com base em 9 analistas que deram avaliações de ações para Day One Biopharmaceuticals Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

6.26 / 7.47Suporte e Resistência

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentimento

By Acuity

162 / 348 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.